Early results of the NCT02740985 phase Ia/b trials using A2AR inhibitor AZD4635 alone or in combination with anti-PD-L1 antibody in 250 PD-1/PD-L1 inhibitor-naive patients with advanced solid tumors, including metastatic castration-resistant prostate cancer (mCRPC), CRC or NSCLC were reported recently (94). This evidence concerns the gene CD274 and colorectal carcinoma.